Novel Mimetic Bispecific Antibody Superior to Standard Care in Hemophilia A

(MedPage Today) -- Bleeding prophylaxis with the investigational factor VIIIa mimetic bispecific antibody Mim8 (denecimig) was superior to on-demand treatment and clotting factor concentrates among patients with hemophilia A with or without inhibitors...
Source
MedPage Today
Opens original article in a new tab



